CRISPR Therapeutics
About:
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Website: http://crisprtx.com/
Twitter/X: crisprtx
Top Investors: New Enterprise Associates, Franklin Templeton, Versant Ventures, Bill & Melinda Gates Foundation, Vertex Pharmaceuticals
Description:
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
$407M
$100M to $500M
Cambridge, Massachusetts, United States
2013-01-01
info(AT)crisprtx.com
Daniel Anderson, Emmanuelle Charpentier, Matthew Porteus, Rodger Novak, Shaun Foy
251-500
2024-02-13
Public
© 2025 bioDAO.ai